{"page_content": "ESG R eport 2021SAFETY OF CLINICAL TRIAL PARTICIPANTS\nDiscussion, by world region, of management process for \nensuring quality and patient safety during clinical trials\nSASB: HC-BP-210A.1\nAgios follows all review and approval procedures required by \napplicable laws and regulations before initiating clinical research. \nAgios protects patient safety and well-being through appropriate \ninformed consent procedures and Good Clinical Practices. For more \ninformation, see Agios\u2019 Code of Business Conduct and Ethics .\nNumber of FDA Sponsor Inspections related to clinical trial \nmanagement and pharmacovigilance that resulted in: (1) \nVoluntary Action Indicated (VAI) and (2) Official Action \nIndicated (OAI)\nSASB: HC-BP-210A.2\n1 FDA sponsor inspection and zero findings (VAI or OAI).\nTotal amount of monetary losses as a result of legal proceedings \nassociated with clinical trials in developing countries\nSASB: HC-BP-210A.3\nNo monetary losses resulting from legal proceedings in 2019. For \nmore information, see Agios\u2019 2020 10-K .\n11", "metadata": {"source": "NASDAQ_AGIO_2020.pdf", "page": 10, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}